Gaucher Disease in Saudi Arabia

How patients in Saudi Arabia access treatment for gaucher disease via Named Patient Program.

About Gaucher Disease

Metabolic

Treatment access in Saudi Arabia

The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.

For patients in Saudi Arabia with gaucher disease whose required therapy is not locally registered, a Named Patient Program pathway typically applies.

How Reserve Meds supports patients with gaucher disease in Saudi Arabia

  1. Patient or physician contacts us with disease details and therapy requested.
  2. We verify eligibility in Saudi Arabia and confirm US supply.
  3. Treating physician in Saudi Arabia issues prescription and justification.
  4. We file Saudi Arabia-specific NPP/personal-import paperwork.
  5. We source the drug from a DSCSA-compliant US specialty wholesaler.
  6. Cold-chain shipment to the patient's physician or hospital pharmacy in Saudi Arabia.

Patient support throughout

  • Case manager from request through delivery.
  • Documentation translation where needed.
  • Physician-to-physician support for clinical justification.
  • Re-supply coordination for chronic therapy.

Start a request

Start a Gaucher Disease request in Saudi Arabia

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp